Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials

Table 3 Meta-analysis of suicide-related events in acute paediatric active comparator-controlled atomoxetine studies–ADHD (FDA-defined approach)

	Atomoxetine			Methylphenidate			MHRR^a(95% CI) p-value	MHID^b(%) (95% CI) p-value
Outcome	No. of events	N	%	No. of events	N	%
Code 1,2,3,4: suicidal behaviour or ideation	1	559	0.18	1	465	0.22	0.52 (95% CI; 0.06, 4.54) P = 0.556	-0.12 (-0.62, 0.38) P = 0.649
Code 4: Suicidal ideation	1	559	0.18	1	465	0.22	0.52 (95% CI; 0.06, 4.54) P = 0.556	-0.12 (-0.62, 0.38) P = 0.649
Code 1,2,3,4,5,6,9: possible suicidal behaviour or ideation	3	559	0.54	2	465	0.43	0.62 (95% CI; 0.14, 2.73) P = 0.528	-0.14 (-0.88, 0.60) P = 0.713

^aMHRR Mantel-Haenszel risk ratio stratified by study. It is the estimate of the percentage among atomoxetine-treated patients over the percentage among methylphenidate-treated patients.
^bMHID Mantel-Haenszel incidence difference stratified by study. It is the estimate of the percentage among atomoxetine-treated patients minus the percentage among methylphenidate-treated patients in percentage units.

ISSN: 1753-2000